Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Regulation Business Practice

Time to Shine

| Maryam Mahdi

What do companies need to consider when developing next-gen medicines for rare diseases?

Discovery & Development Drug Discovery

It’s Live: The Medicine Maker x DNDi Podcast

This 6 episode miniseries will take listeners behind the scenes of a range of projects at the Drugs for Neglected Diseases initiative

Manufacture Bioprocessing - Upstream & Downstream

High Intensity Purification

| Sponsored by Tosoh

How can multi-column chromatography support companies as they set their sights on intensified bioprocesses?

Business & Regulation Supply Chain

Strengthening Supply Chains: Download the Thermo Fisher Scientific eBook

| Sponsored by Thermo Fisher Scientific

The COVID-19 pandemic exposed weaknesses in pharma supply chains. It’s time to address these.

Manufacture Advanced Medicine

No, One Size Does Not Fit All

| Angus Stewart

Is commercializing gene therapy manufacturing an unsolvable problem? We ask an expert on the frontlines.

Business & Regulation Standards & Regulation

Medicare Reveals Coverage Policy for Amyloid mAbs

| Stephanie Sutton

Medicare publishes policy for amyloid mAbs and Alzheimer’s disease. It’s not good news for Aduhelm.

Business & Regulation Digital Technologies

And the Supreme Innovator Is…

| Angus Stewart

Get excited, because the results are in! Find out who won the 2022 Innovation Awards

Business & Regulation COVID-19

A Tale of Two Continents

| Stavros Nicolaou

African vaccine production needs a boost. Here’s how Aspen is working to make that happen.

Business & Regulation Business Practice

Speaking the Language of Pharmaceutical Success

| Maryam Mahdi

We sat down to talk shop with Novo Nordisk Executive Vice President Ludovic Helfgott

Business & Regulation Biosimilars

Brace for Biosimilars!

| Jeff Baldetti

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine